Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing

被引:73
|
作者
Xiao, Wenming [1 ]
Ren, Luyao [2 ,3 ]
Chen, Zhong [4 ]
Fang, Li Tai [5 ]
Zhao, Yongmei [6 ]
Lack, Justin [6 ]
Guan, Meijian [7 ]
Zhu, Bin [8 ]
Jaeger, Erich [9 ]
Kerrigan, Liz [10 ]
Blomquist, Thomas M.
Hung, Tiffany [13 ]
Sultan, Marc [14 ]
Idler, Kenneth [15 ]
Lu, Charles [15 ]
Scherer, Andreas [16 ,17 ]
Kusko, Rebecca [18 ]
Moos, Malcolm [19 ]
Xiao, Chunlin [20 ]
Sherry, Stephen T. [20 ]
Abaan, Ogan D. [9 ,21 ]
Chen, Wanqiu [4 ]
Chen, Xin [4 ]
Nordlund, Jessica [17 ,22 ]
Liljedahl, Ulrika [17 ,23 ]
Maestro, Roberta [17 ,23 ]
Polano, Maurizio [17 ,23 ]
Drabek, Jiri [17 ,24 ]
Vojta, Petr [17 ,24 ]
Koks, Sulev [17 ,25 ,26 ]
Reimann, Ene [17 ,27 ]
Madala, Bindu Swapna [28 ]
Mercer, Timothy [28 ]
Miller, Chris [15 ]
Jacob, Howard [15 ]
Truong, Tiffany [9 ]
Moshrefi, Ali [9 ]
Natarajan, Aparna [9 ]
Granat, Ana [9 ]
Schroth, Gary P. [9 ]
Kalamegham, Rasika [13 ]
Peters, Eric [13 ]
Petitjean, Virginie [14 ]
Walton, Ashley [6 ]
Shen, Tsai-Wei [6 ]
Talsania, Keyur [6 ]
Vera, Cristobal Juan [6 ]
Langenbach, Kurt [10 ]
de Mars, Maryellen [10 ]
Hipp, Jennifer A. [11 ,12 ]
机构
[1] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA
[2] Fudan Univ, Sch Life Sci, Human Phenome Inst, State Key Lab Genet Engn, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[4] Loma Linda Univ, Sch Med, Ctr Genom, Loma Linda, CA 92350 USA
[5] Roche Sequencing Solut Inc, Bioinformat Res & Early Dev, Belmont, CA USA
[6] Frederick Natl Lab Canc Res, Biomed Informat & Data Sci Directorate, Adv Biomed & Computat Sci, Frederick, MD USA
[7] SAS Inst Inc, Cary, NC USA
[8] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA
[9] Illumina Inc, Foster City, CA USA
[10] ATCC, Manassas, VA USA
[11] Univ Toledo, Med Ctr, Dept Med, Toledo, OH USA
[12] Univ Toledo, Med Ctr, Dept Pathol, Toledo, OH USA
[13] Genentech Inc, San Francisco, CA 94080 USA
[14] Novartis Inst Biomed Res, Biomarker Dev, Basel, Switzerland
[15] AbbVie, Genom Res Ctr, Computat Genom, N Chicago, IL 60064 USA
[16] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland
[17] European Infrastruct Translat Med, Amsterdam, Netherlands
[18] Immuneering Corp, Cambridge, MA USA
[19] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA
[20] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bldg 10, Bethesda, MD 20892 USA
[21] Seven Bridges Genom Inc, Cambridge, MA USA
[22] Uppsala Univ, Dept Med Sci, Mol Med & Sci Life Lab, Uppsala, Sweden
[23] NCI, Ctr Riferimento Oncol Aviano, IRCCS, Unit Oncogenet & Funct Oncogen, Aviano, Italy
[24] Palacky Univ Olomouc, Fac Med & Dent, IMTM, Olomouc, Czech Republic
[25] Perron Inst Neurol & Translat Sci, Perth, WA, Australia
[26] Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Perth, WA, Australia
[27] Univ Tartu, Estonian Genome Ctr, Inst Genom, Tartu, Estonia
[28] Kinghorn Canc Ctr, Garvan Inst Med Res, Darlinghurst, NSW, Australia
[29] Natl Inst Metrol, Beijing, Peoples R China
[30] Frederick Natl Lab Canc Res, Canc Res Technol Program, Sequencing Facil, Frederick, MD USA
[31] Ctr Canc Res, Off Sci & Technol Resources, CCR Collaborat Bioinformat Resource, Bethesda, MD USA
[32] NCI, Computat Genom & Bioinformat Branch, Ctr Biomed Informat & Informat Technol, Rockville, MD USA
[33] Digicon, Mclean, VA USA
[34] Virginia Polytech Inst & State Univ, Dept Biol Sci, Blacksburg, VA 24061 USA
[35] Q2 Solut EA Genom, Morrisville, NC USA
[36] NIEHS, Integrat Bioinformat, Durham, NC USA
[37] NHLBI, Bioinformat & Computat Biol Core, NIH, Bldg 10, Bethesda, MD 20892 USA
[38] Sentieon Inc, Mountain View, CA USA
[39] NIH, Ctr Informat Technol, Bldg 10, Bethesda, MD 20892 USA
[40] AstraZeneca, Gaithersburg, MD USA
[41] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA
[42] Weill Cornell Med, Dept Physiol & Biophys, New York, NY USA
[43] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[44] US FDA, Off Chief Scientist, Off Commissioner, Silver Spring, MD USA
[45] NCI, Lymphoid Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院; 中国国家自然科学基金;
关键词
SOMATIC POINT MUTATIONS; CLINICAL VALIDATION; READ ALIGNMENT; QUALITY; SAMPLES; DNA;
D O I
10.1038/s41587-021-00994-5
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recommendations are given on optimal read coverage and selection of calling algorithm to maximize the reproducibility of cancer mutation detection in whole-genome or whole-exome sequencing. Clinical applications of precision oncology require accurate tests that can distinguish true cancer-specific mutations from errors introduced at each step of next-generation sequencing (NGS). To date, no bulk sequencing study has addressed the effects of cross-site reproducibility, nor the biological, technical and computational factors that influence variant identification. Here we report a systematic interrogation of somatic mutations in paired tumor-normal cell lines to identify factors affecting detection reproducibility and accuracy at six different centers. Using whole-genome sequencing (WGS) and whole-exome sequencing (WES), we evaluated the reproducibility of different sample types with varying input amount and tumor purity, and multiple library construction protocols, followed by processing with nine bioinformatics pipelines. We found that read coverage and callers affected both WGS and WES reproducibility, but WES performance was influenced by insert fragment size, genomic copy content and the global imbalance score (GIV; G > T/C > A). Finally, taking into account library preparation protocol, tumor content, read coverage and bioinformatics processes concomitantly, we recommend actionable practices to improve the reproducibility and accuracy of NGS experiments for cancer mutation detection.
引用
收藏
页码:1141 / +
页数:27
相关论文
共 50 条
  • [21] Whole-exome and whole-genome sequencing in chronic lymphocytic leukemia: new biomarkers to target
    Hobeika, Charbel
    Rached, Gaelle
    Chebly, Alain
    Chouery, Eliane
    Kourie, Hampig Raphael
    [J]. PHARMACOGENOMICS, 2020, 21 (13) : 957 - 962
  • [22] BALSA: integrated secondary analysis for whole-genome and whole-exome sequencing, accelerated by GPU
    Luo, Ruibang
    Wong, Yiu-Lun
    Law, Wai-Chun
    Lee, Lap-Kei
    Cheung, Jeanno
    Liu, Chi-Man
    Lam, Tak-Wah
    [J]. PEERJ, 2014, 2
  • [23] Matched whole-genome sequencing and whole-exome sequencing with circulating tumor DNA (ctDNA) analysis are complementary modalities in clinical practice
    Imperial, R.
    Nazer, M.
    Pappas, S. G.
    Kuzel, T.
    El-Rayes, B.
    Pluard, T.
    Levy, M.
    Subramanian, J.
    Masood, A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 811 - 811
  • [24] Metastatic cancer whole-exome sequencing in daily practice
    Reda, M.
    Richard, C.
    Niogret, J.
    Fumet, J-D.
    Bertaut, A.
    Blanc, J.
    Truntzer, C.
    Desmoulins, I.
    Ladoire, S.
    Bengrine-Lefevre, L.
    Isambert, N.
    Hervieu, A.
    Lepage, C.
    Foucher, P.
    Borg, C.
    Arnould, L.
    Nambot, S.
    Faivre, L.
    Boidot, R.
    Ghiringhelli, F.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 765 - 765
  • [25] Whole-genome sequencing offers additional but limited clinical utility compared with reanalysis of whole-exome sequencing
    Alfares, Ahmed
    Aloraini, Taghrid
    Al Subaie, Lamia
    Alissa, Abdulelah
    Al Qudsi, Ahmed
    Alahmad, Ahmed
    Al Mutairi, Fuad
    Alswaid, Abdulrahman
    Alothaim, Ali
    Eyaid, Wafaa
    Albalwi, Mohammed
    Alturki, Saeed
    Alfadhel, Majid
    [J]. GENETICS IN MEDICINE, 2018, 20 (11) : 1328 - 1333
  • [26] Accelerated somatic mutation calling tool for whole-genome and whole-exome sequencing data from heterogenous tumor samples
    Ji, Shuangxi
    Zhu, Tong
    Sethia, Ankit
    Montierth, Matthew D.
    Wang, Wenyi
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [27] miRMut: Annotation of mutations in miRNA genes from human whole-exome or whole-genome sequencing
    Urbanek-Trzeciak, Martyna O.
    Kozlowski, Piotr
    Galka-Marciniak, Paulina
    [J]. STAR PROTOCOLS, 2022, 3 (01):
  • [28] Accurate rare variant phasing of whole-genome and whole-exome sequencing data in the UK Biobank
    Hofmeister, Robin J.
    Ribeiro, Diogo M.
    Rubinacci, Simone
    Delaneau, Olivier
    [J]. NATURE GENETICS, 2023, 55 (07) : 1243 - +
  • [29] Accurate rare variant phasing of whole-genome and whole-exome sequencing data in the UK Biobank
    Robin J. Hofmeister
    Diogo M. Ribeiro
    Simone Rubinacci
    Olivier Delaneau
    [J]. Nature Genetics, 2023, 55 : 1243 - 1249
  • [30] Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature
    Schwarze, Katharina
    Buchanan, James
    Taylor, Jenny C.
    Wordsworth, Sarah
    [J]. GENETICS IN MEDICINE, 2018, 20 (10) : 1122 - 1130